573 related articles for article (PubMed ID: 28209630)
1. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells.
Lu QK; Fan C; Xiang CG; Wu B; Lu HM; Feng CL; Yang XQ; Li H; Tang W
Acta Pharmacol Sin; 2022 Feb; 43(2):376-386. PubMed ID: 33850274
[TBL] [Abstract][Full Text] [Related]
4. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.
Beyer C; Huang J; Beer J; Zhang Y; Palumbo-Zerr K; Zerr P; Distler A; Dees C; Maier C; Munoz L; Krönke G; Uderhardt S; Distler O; Jones S; Rose-John S; Oravecz T; Schett G; Distler JH
Ann Rheum Dis; 2015 Jun; 74(6):1317-24. PubMed ID: 24618263
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
[TBL] [Abstract][Full Text] [Related]
6. Antifibrotic effect of apremilast in systemic sclerosis dermal fibroblasts and bleomycin-induced mouse model.
Higuchi T; Takagi K; Tochimoto A; Ichimura Y; Hirose H; Sawada T; Shibata N; Harigai M; Kawaguchi Y
Sci Rep; 2023 Nov; 13(1):19378. PubMed ID: 37938601
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
8. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.
Zhang Y; McCormick LL; Desai SR; Wu C; Gilliam AC
J Immunol; 2002 Mar; 168(6):3088-98. PubMed ID: 11884483
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
[TBL] [Abstract][Full Text] [Related]
10. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J
Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566
[TBL] [Abstract][Full Text] [Related]
11. Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Schafer PH; Adams M; Horan G; Truzzi F; Marconi A; Pincelli C
Drugs R D; 2019 Dec; 19(4):329-338. PubMed ID: 31598889
[TBL] [Abstract][Full Text] [Related]
12. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
[TBL] [Abstract][Full Text] [Related]
13. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.
Udalov S; Dumitrascu R; Pullamsetti SS; Al-tamari HM; Weissmann N; Ghofrani HA; Guenther A; Voswinckel R; Seeger W; Grimminger F; Schermuly RT
BMC Pulm Med; 2010 May; 10():26. PubMed ID: 20444277
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Li H; Fan C; Feng C; Wu Y; Lu H; He P; Yang X; Zhu F; Qi Q; Gao Y; Zuo J; Tang W
Br J Pharmacol; 2019 Jul; 176(13):2209-2226. PubMed ID: 30883697
[TBL] [Abstract][Full Text] [Related]
15. Combination of 5-aminolevulinic acid and iron prevents skin fibrosis in murine sclerodermatous graft-versus-host disease.
Liu C; Yang X; Zhu P; Fujino M; Ito H; Takahashi K; Nakajima M; Tanaka T; Wang J; Zhuang J; Zou H; Li XK
Exp Dermatol; 2018 Oct; 27(10):1104-1111. PubMed ID: 29978518
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
Zhang Y; Zhu H; Layritz F; Luo H; Wohlfahrt T; Chen CW; Soare A; Bergmann C; Ramming A; Groeber F; Reuter C; Fornasini G; Soukhareva N; Schreiber B; Ramamurthy S; Amann K; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Aug; 72(8):1385-1395. PubMed ID: 32182396
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
[TBL] [Abstract][Full Text] [Related]
18. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
19. Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model.
Hasegawa T; Utsunomiya A; Chino T; Kasamatsu H; Shimizu T; Matsushita T; Obara T; Ishii N; Ogasawara H; Ikeda W; Imai T; Oyama N; Hasegawa M
Arthritis Res Ther; 2024 May; 26(1):94. PubMed ID: 38702742
[TBL] [Abstract][Full Text] [Related]
20. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
